ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2022

Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland.

Michaela Barbier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.